Drugs / Taminadenant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02403193 | Oct 2015 → Oct 2021 | non-small cell lung carcinoma | Palobiofarma SL | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Taminadenant | “Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.” PMID 35254415 ↗ Jun 2022 |
| Known as | NIR178 | “Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.” PMID 35254415 ↗ Jun 2022 |
| Known as | PBF509 | “Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.” PMID 35254415 ↗ Jun 2022 |
| Action | Inhibit | “Taminadenant (PBF509/NIR178) is an A2AR antagonist able to reactivate the antitumor immune response.” PMID 35254415 ↗ Jun 2022 |